Our meta‐analysis showed that glioma cases have significantly reduced BDNF plasma concentrations compared to controls, with lower levels in higher pathological grades, suggesting for the first time that plasma BDNF could be both a diagnostic and a prognostic marker in glioma. This evidence concerns the gene BDNF and central nervous system cancer.